期刊
CANCER & METABOLISM
卷 10, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40170-022-00286-9
关键词
Adaptation; Colorectal cancer; Glucose; Irinotecan; Metabolism; p53; Warburg effect
资金
- DFG [RTG1715 SP13, 393547839-SFB 1361]
- Projekt DEAL
- Boehringer Ingelheim Fonds (BIF)
- CRUK Career Development Fellowship [C53309/A19702]
- Graduate Academy (GA) of the Friedrich Schiller University (FSU) Jena
- Deutsche Forschungsgemeinschaft [KR2291/9-1, 427404172/12-1, 445785155/14-1, 469954457/15-1, 495271833, 496927074/16-1]
- Wilhelm Sander-Stiftung [2019.086.1]
- Brigitte und Dr. Konstanze Wegener-Stiftung [65]
- Richard Winter Stiftung
Chemotherapeutics that cause DNA replication stress increase the metabolism of colorectal cancer (CRC) cells, and glucose restriction might improve the effectiveness of classical chemotherapy against p53-positive cells.
Background: Metabolic adaptations can allow cancer cells to survive DNA-damaging chemotherapy. This unmet clinical challenge is a potential vulnerability of cancer. Accordingly, there is an intense search for mechanisms that modulate cell metabolism during anti-tumor therapy. We set out to define how colorectal cancer CRC cells alter their metabolism upon DNA replication stress and whether this provides opportunities to eliminate such cells more efficiently. Methods: We incubated p53-positive and p53-negative permanent CRC cells and short-term cultured primary CRC cells with the topoisomerase-1 inhibitor irinotecan and other drugs that cause DNA replication stress and consequently DNA damage. We analyzed pro-apoptotic mitochondrial membrane depolarization and cell death with flow cytometry. We evaluated cellular metabolism with immunoblotting of electron transport chain (ETC) complex subunits, analysis of mitochondrial mRNA expression by qPCR, MTT assay, measurements of oxygen consumption and reactive oxygen species (ROS), and metabolic flux analysis with the Seahorse platform. Global metabolic alterations were assessed using targeted mass spectrometric analysis of extra- and intracellular metabolites. Results: Chemotherapeutics that cause DNA replication stress induce metabolic changes in p53-positive and p53-negative CRC cells. Irinotecan enhances glycolysis, oxygen consumption, mitochondrial ETC activation, and ROS production in CRC cells. This is connected to increased levels of electron transport chain complexes involving mitochondrial translation. Mass spectrometric analysis reveals global metabolic adaptations of CRC cells to irinotecan, including the glycolysis, tricarboxylic acid cycle, and pentose phosphate pathways. P53-proficient CRC cells, however, have a more active metabolism upon DNA replication stress than their p53-deficient counterparts. This metabolic switch is a vulnerability of p53-positive cells to irinotecan-induced apoptosis under glucose-restricted conditions. Conclusion: Drugs that cause DNA replication stress increase the metabolism of CRC cells. Glucose restriction might improve the effectiveness of classical chemotherapy against p53-positive CRC cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据